TIGIT and cancer: To verify whether NLRP4-eco was cancer-type conserved, we examined NLRP4-OE in MC38 cell-line, and confirmed the same anti-tumor capacity mediated by iNOS+ M1, TIGIT+TNFA+ NK and CD103+ DC (Fig. S2e-f), along with favorable OS (Fig. S2g), further emphasizing the unique landscape of NLRP4-eco across different cancer types.